Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.31 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket: danvatirsen | 0.60 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 171 Parkinson's papers of 44,116 | 0.32 |
| pathways Reactome | 42 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 1239
Sealed predictions
- STAT3 in dopamine neurons, braak+0.14 (p 0.722) → +0.20 (p 0.613)receipt 1244
Swarm cases
receipt 1244: STAT3 in dopamine neurons, braak
- power
- full sample +0.08 (p 0.754, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.08 (p 0.754, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.03 (p 0.901, n 18). could be the mix.
- skeptic
- leave-one-out range -0.02 to +0.20, sign flips 2; without severely affected donors +0.08 (p 0.754, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.62 (p 0.0057, n 18) vs +0.08 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for STAT3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up STAT3 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.13 p 0.657 (needs p < 0.0010)
Receipts
loading the receipts